These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. Riall TS; Stager VM; Nealon WH; Townsend CM; Kuo YF; Goodwin JS; Freeman JL J Am Coll Surg; 2007 May; 204(5):803-13; discussion 813-4. PubMed ID: 17481488 [TBL] [Abstract][Full Text] [Related]
8. The role of inflammation in pancreatic cancer. Hausmann S; Kong B; Michalski C; Erkan M; Friess H Adv Exp Med Biol; 2014; 816():129-51. PubMed ID: 24818722 [TBL] [Abstract][Full Text] [Related]
9. Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pancreatic ductal adenocarcinoma. Date K; Ohtsuka T; Nakamura S; Mochidome N; Mori Y; Miyasaka Y; Oda Y; Nakamura M Surgery; 2018 Feb; 163(2):291-299. PubMed ID: 29221879 [TBL] [Abstract][Full Text] [Related]
10. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Ikegawa T; Masuda A; Sakai A; Toyama H; Zen Y; Sofue K; Nakagawa T; Shiomi H; Takenaka M; Kobayashi T; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Azuma T Pancreatology; 2018 Jun; 18(4):399-406. PubMed ID: 29685673 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis of pernicious anemia and the risk of pancreatic cancer. Shah P; Rhim AD; Haynes K; Hwang WT; Yang YX Pancreas; 2014 Apr; 43(3):422-6. PubMed ID: 24622073 [TBL] [Abstract][Full Text] [Related]
13. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer. Bogdanski AM; van Hooft JE; Boekestijn B; Bonsing BA; Wasser MNJM; Klatte DCF; van Leerdam ME Fam Cancer; 2024 Aug; 23(3):323-339. PubMed ID: 38619782 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology of intraductal papillary mucinous neoplasms of the pancreas: sex differences between 3 geographic regions. Ingkakul T; Warshaw AL; Fernández-Del Castillo C Pancreas; 2011 Jul; 40(5):779-80. PubMed ID: 21673537 [No Abstract] [Full Text] [Related]
15. Light at Night and Risk of Pancreatic Cancer in the NIH-AARP Diet and Health Study. Xiao Q; Jones RR; James P; Stolzenberg-Solomon RZ Cancer Res; 2021 Mar; 81(6):1616-1622. PubMed ID: 33514513 [TBL] [Abstract][Full Text] [Related]
17. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Al Haddad AH; Adrian TE Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674 [TBL] [Abstract][Full Text] [Related]
18. [Epidemiology of pancreatic ductal adenocarcinoma]. Sato R; Kishiwada M; Isaji S Nihon Rinsho; 2015 Mar; 73 Suppl 3():95-9. PubMed ID: 25856992 [No Abstract] [Full Text] [Related]
19. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M Cancer Treat Rev; 2022 Mar; 104():102357. PubMed ID: 35184001 [TBL] [Abstract][Full Text] [Related]
20. Predisposing factors for pancreatic adenocarcinoma: What is the role of imaging? Vullierme MP; Lagadec M Diagn Interv Imaging; 2016 Dec; 97(12):1233-1240. PubMed ID: 27816353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]